Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial
Details
Publication Year 2024-02-10,Volume 42,Issue #5,Page 571-583
Journal Title
Journal of Clinical Oncology
Publication Type
Research article
Abstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Publisher
American Society of Clinical Oncology
Keywords
Humans; Male; BRCA1 Protein/genetics; BRCA2 Protein/genetics; Kaplan-Meier Estimate; Phthalazines/therapeutic use; Piperazines/therapeutic use; *Prostatic Neoplasms, Castration-Resistant/drug therapy/genetics
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1200/jco.23.00339
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-03-13 05:27:09
Last Modified: 2024-03-13 05:27:28

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙